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Clinical PerspectiveWhat Is New?A single base change in *Stim1* creates susceptibility to hypertensive renal injury in spontaneously hypertensive rats.The *Stim1* mutation disrupts calcium signaling in lymphocytes and impairs T‐cell effector and regulatory function.Defects in T‐cell function may promote autoantibody formation and antibody‐mediated renal injury.What Are the Clinical Implications?Identification of genetic variants that enhance susceptibility to hypertensive renal disease in rodent models can uncover functional pathways that may be involved in disease pathogenesis in humans.

Introduction {#jah34776-sec-0008}
============

Hypertension increases the risk of progressive renal disease. This risk is strongly influenced by heritable factors.[1](#jah34776-bib-0001){ref-type="ref"}, [2](#jah34776-bib-0002){ref-type="ref"}, [3](#jah34776-bib-0003){ref-type="ref"} Hypertension is common, but not all hypertensives will experience accelerated loss of renal function. Presence of a first‐degree relative with end‐stage renal disease significantly enhances the risk that hypertensive nephrosclerosis will culminate in end‐stage renal disease.[3](#jah34776-bib-0003){ref-type="ref"} Among blacks, the best predictor of individual dialysis risk is the existence of a close relative who has experienced end‐stage renal disease.[4](#jah34776-bib-0004){ref-type="ref"} These observations indicate the role of heritable genetic variation in disease pathogenesis. An independent genetic susceptibility to risk of renal disease in hypertension is also demonstrated in the spontaneously hypertensive rat (SHR) model in which similarly hypertensive SHR lines differ in their susceptibility to renal disease.[5](#jah34776-bib-0005){ref-type="ref"}, [6](#jah34776-bib-0006){ref-type="ref"} The pathogenic mechanism of hypertensive renal injury is poorly understood. Consequently, efforts are under way to dissect out the causative genetic variation that creates disease risk in the expectation that such insight may uncover disease mechanisms.[7](#jah34776-bib-0007){ref-type="ref"}

In this study we investigated the genetic mechanism of hypertensive renal injury in the SHR by investigation of 2 SHR lineages, injury‐susceptible SHR‐A3 (also known as the stroke‐prone SHR) and SHR‐B2, a line that resists hypertensive end‐organ disease.[5](#jah34776-bib-0005){ref-type="ref"}, [8](#jah34776-bib-0008){ref-type="ref"}, [9](#jah34776-bib-0009){ref-type="ref"} Although these lines have a divergent heritable risk for progressive renal disease, they are 87% genetically identical and share in common alleles that create hypertension.[7](#jah34776-bib-0007){ref-type="ref"} Our previous studies of this model have suggested a multigene inheritance of risk of hypertensive renal injury involving genetic variation affecting immune function.[5](#jah34776-bib-0005){ref-type="ref"}, [8](#jah34776-bib-0008){ref-type="ref"} The immunoglobulin heavy chain gene is highly divergent between these SHR lines, and transfer of this immunoglobulin genetic variation from resistant to susceptible SHR lines reduces hypertensive renal injury, indicating a role for antibodies in this disease.[9](#jah34776-bib-0009){ref-type="ref"}, [10](#jah34776-bib-0010){ref-type="ref"}

Whole‐genome sequence analysis of SHR‐A3 and SHR‐B2 lines led to the discovery of a deleterious mutation affecting the gene *Stim1* in SHR‐A3.[7](#jah34776-bib-0007){ref-type="ref"} STIM1 is an endoplasmic reticulum (ER) Ca^2+^ sensor that plays a central role in lymphocyte effector and regulatory function.[11](#jah34776-bib-0011){ref-type="ref"} Stimulation of T‐ (TCR) or B‐cell receptors induces the rapid emptying of Ca^2+^ from lymphocyte ER stores. Ca^2+^ store depletion activates STIM1, which triggers opening of the plasma membrane (PM) calcium channel encoded by *Orai1*, thereby facilitating a large and sustained influx of extracellular Ca^2+^.[12](#jah34776-bib-0012){ref-type="ref"}, [13](#jah34776-bib-0013){ref-type="ref"} This process of capacitative, or store‐operated, Ca^2+^ entry is required for activation of the protein phosphatase calcineurin. Calcineurin activation results in dephosphorylation and nuclear localization of nuclear factor of activated T cells (NFAT), a key transcription factor that modulates cytokine production and coordinates T‐cell immune functions and proliferation.[14](#jah34776-bib-0014){ref-type="ref"} STIM1 activation is also necessary for the cellular metabolic reprogramming associated with lymphocyte activation.[15](#jah34776-bib-0015){ref-type="ref"} In the present article we characterize the immune phenotypes arising from *Stim1* mutation. We rescued the *Stim1* mutation in SHR‐A3 by replacement of the defective allele with wild‐type *Stim1* and determined the effects of rescue on immune phenotypes and the emergence and extent of hypertensive renal injury. Because autoantibody‐mediated immunity has been reported in *Stim1* deletion,[16](#jah34776-bib-0016){ref-type="ref"}, [17](#jah34776-bib-0017){ref-type="ref"}, [18](#jah34776-bib-0018){ref-type="ref"} we have sought evidence of autoantibody formation in SHR‐A3.

Materials and Methods {#jah34776-sec-0009}
=====================

Data Availability {#jah34776-sec-0010}
-----------------

The data that support the findings of this study are available from the corresponding author on reasonable request.

Animals and Treatments {#jah34776-sec-0011}
----------------------

The Institutional Animal Welfare Committee prospectively reviewed and approved all animal experiments and protocols. Studies were performed on male animals from the injury‐susceptible spontaneously hypertensive‐A3 (SHR‐A3) and the injury‐resistant SHR‐B2 rat lines, previously rederived and maintained in our Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)‐approved specific pathogen‐free facility. These lines and their origins before transfer to our laboratory have been recorded at the Rat Genome Database (<https://rgd.mcw.edu/rgdweb/search/strains.html>), which has applied the following identifiers: SHR‐A3, RGD ID=8142383, Symbol=SHRSP/BbbUtx; SHR‐B2, RGD ID=8142385, Symbol=SHR/Utx. Animals were provided a standard rodent chow diet and drinking water ad libitum. Animals aged 18 to 20 weeks were used for in vitro immune phenotyping experiments.

*Stim1* Congenic Line Creation and Confirmation {#jah34776-sec-0012}
-----------------------------------------------

The *Stim1* mutation resides in an extended haplotype block of identity by descent in which the same genetic background arising from a single common ancestor has been fixed in both SHR‐A3 and SHR‐B2. The *Stim1*‐encompassing block extends for ≈45 Mb on chromosome 1 (chr1:163‐208 Mb) and, except for the *Stim1* mutation, contains no other nonsynonymous coding sequence variants between SHR‐A3 and SHR‐B2 as determined using Annovar software[19](#jah34776-bib-0019){ref-type="ref"} (Open Bioinformatics Foundation, Basel, Switzerland) to analyze variant call format files derived from alignment to the rat reference genome of SHR‐A3 and SHR‐B2 genome sequences. Congenic transfer across this block allows rescue of the defective SHR‐A3 *Stim1* allele while avoiding transmission of any other coding sequence variation. Congenic line construction began by crossing of parental line animals (SHR‐A3 males and SHR‐B2 females) to generate the F1 progeny. These progeny were backcrossed into SHR‐A3 animals for 5 generations. Backcrossed animals were genotyped at each generation using a previously described panel of ≈200 single‐nucleotide polymorphism (SNP) markers to allow speedy congenic selection of optimal animals (highest loss of SHR‐B2 background alleles while retaining the introgressed SHR‐B2 *Stim1* haplotype block).[9](#jah34776-bib-0009){ref-type="ref"} The final congenic line was created by mating male and female animals from the previous backcross and selecting progeny that were homozygous for SHR‐B2 alleles at the *Stim1* locus and for SHR‐A3 alleles at the other genotyped loci.

Lymphocyte Isolation {#jah34776-sec-0013}
--------------------

Peripheral blood was collected from the abdominal aorta of isoflurane‐anesthetized rats (16‐18 weeks old). Lymphocytes were isolated from whole blood using lymphocyte separation medium (Lonza, Allendale, NJ) according to the manufacturer\'s directions. Briefly, whole blood was diluted 1:1 with sterile buffered saline and layered on top of lymphocyte separation medium at a ratio of 3:2 followed by centrifugation at 400*g* for 20 minutes at 4°C. Lymphocytes were collected and washed twice followed by centrifugation at 70*g* for 10 minutes to remove platelets. For isolation of splenocytes, spleens were cut into small fragments and passed through a 70‐μm cell strainer into a 50‐mL conical tube. Collected cells were washed, the pellet was resuspended in 5 mL erythrocyte lysis buffer, and lysis was carried out for 10 minutes at 25°C with gentle shaking. After red cell lysis, splenocytes were collected by centrifugation. Lymphocytes were collected from abdominal aortic lymph nodes in a similar manner. For renal lymphocyte counts, we followed the isolation method detailed by Martina et al.[20](#jah34776-bib-0020){ref-type="ref"} Cells were either resuspended in complete Roswell Park Memorial Institute (RPMI)‐1640 medium (RPMI containing 10% FBS, 100 U/mL penicillin‐streptomycin, 4 mmol/L [l]{.smallcaps}‐glutamine, 1 mmol/L sodium pyruvate, 1% nonessential amino acids, 1% RPMI vitamins, 10 mmol/L HEPES, and 50 μmol/L β‐mercaptoethanol), or in flow cytometry staining buffer, based on downstream applications.

Flow Cytometry {#jah34776-sec-0014}
--------------

Lymphocytes were stained according to standard protocols. Briefly, for staining surface markers, cells were resuspended in fluorescence‐activated cell‐sorting (FACS) buffer at a concentration of 2×10^6^ cells/mL. Nonspecific antibody binding was blocked with anti--rat CD32 antibody (BD Biosciences, Franklin Lakes, NJ) followed by staining with specific antibodies (1:1000, all from BioLegend, San Diego, CA) for 60 minutes on ice in the dark. Antibodies used for flow cytometry included FITC‐CD3, APC‐CD3, PECy7‐CD4, PE‐CD25, FITC‐CD8, APC‐CD45RA, and Alexa Fluor 647‐Foxp3. Intracellular Foxp3 staining was performed after cell surface staining using the True Nuclear transcription factor staining kit (BioLegend) according to the manufacturer\'s protocol. Stained cells were washed twice and resuspended in FACS buffer and analyzed or sorted on a BD FACSAria II flow cytometer (BD Biosciences).

Western Blotting for STIM1 Protein Expression {#jah34776-sec-0015}
---------------------------------------------

Lymphocyte lysates were prepared by sonication in 300 μL of cell lysis buffer (Cell Signaling Technologies, Danvers, MA) with protease and phosphatase inhibitors (Sigma Aldrich, St. Louis, MO). Protein concentration was determined using the bicinchoninic acid assay kit (ThermoFisher Scientific, Waltham, MA). Samples were diluted with lysis buffer, denatured, and reduced in Laemmli buffer supplemented with β‐mercaptoethanol at 5% final concentration for 10 minutes at 100°C to obtain the final protein concentration of 2 μg/μL. Lysate proteins (30 μL/lane) were separated on 4% to 20% polyacrylamide gels at 70 V for 4 hours and transferred to nitrocellulose membrane for 1.5 hours at 100 V. Membranes were incubated with primary antibodies for 2 hours at room temperature. We used primary antibodies against the N‐terminus of STIM1 (1:3000 dilution, Sigma‐Aldrich, \#S6072) and anti--β‐actin (1:2000, BioLegend). Membranes were washed 3 times in PBS‐Tween and incubated with peroxidase‐conjugated goat anti--rabbit secondary antibodies (1:5000, Santa Cruz Biotechnology, Dallas, TX) for 1 hour at room temperature. Blots were quantified using ImageJ 1.48 software (NIH, Bethesda, MD). The intensities of the studied protein bands were normalized to the intensities of the corresponding actin bands.

Store‐Operated Calcium Entry {#jah34776-sec-0016}
----------------------------

Flow cytometry with the nonratiometric dye Fluo‐3AM (Promokine, Heidelberg, Germany) was used to assess store‐operated calcium entry (SOCE) in peripheral blood lymphocytes. Lymphocytes (2×10^6^ cells/mL) were stained for surface CD3 and CD4 as described above and then loaded with Fluo‐3AM (final concentration 1 μmol/L) for 30 minutes at 37°C in complete RPMI. Cells were washed and resuspended in 2 mL Ca^2+^‐free Ringer solution. Fluorescence measurements were acquired on a FACSCalibur (BD Biosciences) flow cytometer. CD4^+^ T cells were gated using cell surface markers. Baseline Ca^2+^ measurements were made for 2 minutes followed by the addition of the ER Ca‐ATPase inhibitor thapsigargin (2 μmol/L) for 5 minutes. SOCE was induced by the addition of 2 mmol/L Ca^2+^, and data were recorded for 5 minutes. For TCR‐induced SOCE, labeled lymphocytes were incubated with biotin--anti‐CD3 (1:1000, BD Biosciences) for 5 minutes before baseline measurements were done. After recording of the baseline for 2 minutes, CD3 was cross‐linked by streptavidin (1:3000, ThermoFisher Scientific) followed by the addition of 2 mmol/L Ca^2+^ for 5 minutes to induce SOCE. Data were analyzed using FlowJo (Treestar, Ashland, OR) software. EGTA and ionomycin (2 μmol/L) were used to calculate maximal and minimal fluorescence values of Ca^2+^, and actual \[Ca^2+^\]~i~ was calculated according to the equation: \[Ca²⁺\]~i~ = Kd × {\[F ‐ (F~min~)\] × \[(F~max~ ‐ F)\]} where F is the fluorescence of the indicator at the experimental concentration, F~min~ is the fluorescence in the absence of calcium, and F~max~ is the fluorescence of the indicator at saturated calcium concentration. The Kd for Fluo‐3 under our experimental conditions was 325 nM.

NFAT Nuclear Translocation {#jah34776-sec-0017}
--------------------------

Peripheral blood lymphocytes (1×10^6^ cells/mL) were stimulated with PMA (phorbol myristate acetate, 10 nmol/L) and ionomycin (2 μmol/L) for 1 hour at 37°C. Following treatment, cells were fixed with 4% paraformaldehyde in 0.1 phosphate buffer (Electron Microscopy Sciences, Hatfield, PA) for 10 minutes. Lymphocytes were then centrifuged in a cytospin for 5 minutes at 90*g* onto slides. Cells were then permeabilized by a 5‐minute incubation with 0.5% Triton X‐100 in PBS, followed by washing in PBS for 5 minutes. Nonspecific binding was blocked with Protein Block (BioGenex, San Ramon, CA) for 1 hour at room temperature. Cells were incubated with anti‐NFATc1 clone‐7A6 (BioLegend) overnight at 4°C followed by washing and a 1‐hour incubation at room temperature with Alexa 488‐conjugated goat anti--mouse IgG (BioLegend 405319). Nuclear counterstaining was performed with 5 mmol/L Draq5 (Cell Signaling Technology, Danvers, MA; 4084S) for 1 hour. Images were acquired with a ×63 oil‐immersion objective (NA1.4) of a Leica TCS SP5 confocal microscope. Single optical sections were obtained with high--numerical aperture lens (×63 with an additional ×2 software zoom) to determine the percentage of NFATc1‐nuclear cells. At least 200 cells were analyzed from each group with 3 independent replicates.

Cytokine Production in Stimulated T Cells {#jah34776-sec-0018}
-----------------------------------------

CD4^+^ T cells (2×10^5^ cells) sorted by FACS from peripheral blood were seeded into 96‐well plates and stimulated with PMA (10 nmol/L) and ionomycin (2 μmol/L) (both from eBiosciences, San Diego, CA) for 4 hours at 37°C. For TCR‐induced cytokine production, cells were similarly seeded onto wells precoated with 5 μg/mL anti‐CD3 (clone G4.18, eBiosciences). Soluble anti‐CD28 (2.5 μg/mL, clone JJ319, BD Biosciences) was added for 24 hours at 37°C to activate T cells. Cells were also pretreated with the ORAI1 inhibitor Pyr6 (5 μmol/L, Tocris Biosciences, Bristol, UK) for 15 minutes before the addition of anti‐CD28. ELISA was used to quantify cytokine levels in the cell culture supernatants according to standard protocols. Briefly, plates were coated with primary antibodies to interferon‐γ (BioLegend) at a concentration of 2 μg/mL followed by incubation with cell culture supernatants for 2 hours at 25°C. The total bound antigen was quantified using biotinylated secondary antibodies (1:1000) and visualized using the horseradish peroxidase/streptavidin‐TMB system (Bethyl Laboratories, Montgomery, TX). Interleukin (IL)‐2 was quantified in a similar manner using a kit‐based assay (R&D Systems, Minneapolis, MN).

T‐Cell Proliferation and Activation‐Induced Cell Death {#jah34776-sec-0019}
------------------------------------------------------

To assess T‐cell proliferation, CD3^+^ lymphocytes (1×10^6^ cells/mL) were incubated with 5 μmol/L carboxyfluorescein succinimidyl ester (CFSE, BioLegend) for 20 minutes at 37°C protected from light before costimulation with CD3/CD28. CFSE fluorescence was quenched by the addition of 5 mL complete RPMI, and cells were collected by centrifugation at 400*g* for 5 minutes. CFSE‐loaded cells were resuspended in prewarmed complete RPMI medium and were stimulated with CD3/CD28 for 48 hours as described above. At the end of the proliferation protocol, T cells were stained for surface CD4, and CFSE dilution was assessed by flow cytometry (BD FACSAria II). For activation‐induced cell death, T cells were costimulated with CD3/CD28 followed by a second stimulation with CD3/CD28 for 24 hours. At the end of the restimulation, apoptotic cells were identified using the FITC Annexin V Apoptosis detection kit (BioLegend) according to the manufacturer\'s protocol.

Assessment of Renal Injury {#jah34776-sec-0020}
--------------------------

Periodic acid Schiff--stained kidney sections were scored for glomerular and tubular injury in 40‐week‐old animals as previously described.[5](#jah34776-bib-0005){ref-type="ref"}, [8](#jah34776-bib-0008){ref-type="ref"} Kidneys were collected by ventral laparotomy under isoflurane anesthesia at the end of the treatment period. Kidneys were cut into radial sections, fixed in 4% buffered formalin, and embedded in paraffin using standard techniques. Four‐micrometer sections were stained with periodic acid Schiff stain and were evaluated for renal injury by an experienced renal pathologist who was blinded to the treatment groups. Injury scores were obtained by randomly sampling 20 glomeruli and 10 cortical tubular fields per animal. Scores were graded according to degree of injury on a scale from 1 to 5. Glomerular injury was graded as follows: (0) no histologic abnormality; (1) mild mesangial thickening only; (2) moderate mesangial expansion without thickened capillary loops; (3) severe mesangial expansion, thickened capillary loops, or segmental sclerosis; (4) global or \>50% segmental sclerosis. Tubulointerstitial disease was graded as (0) no injury; (1) mild patchy fibrosis, infiltrate \<10 cells/high‐power field; (2) mild to moderate fibrosis, patchy tubular atrophy, infiltrate \>10 cells/high‐power field; (3) diffuse tubular atrophy, moderate fibrosis, proteinaceous casts, diffuse interstitial infiltrate; (4) severe interstitial fibrosis with strong diffuse cellular infiltrates or tubular atrophy.

Urinary albumin excretion was assessed as previously described.[5](#jah34776-bib-0005){ref-type="ref"} Urine was collected directly from the bladder at the time of the telemetry probe implantation surgery and again at the end of the study period. Urinary albumin excretion was assessed as the ratio of urinary albumin:creatinine. Urinary creatinine concentrations were quantified by high‐performance liquid chromatography. A rat‐specific ELISA kit (Bethyl Laboratories) was used to determine urinary albumin concentrations according to the manufacturer\'s protocols.

For urinary biomarker analysis, we investigated the excretion of KIM‐1 (kidney injury molecule 1, Havcr1 \[hepatitis A virus cell receptor 1\]), Lcn2 (lipocalin 2, also known as NGAL \[neutrophil gelatinase‐associated lipocalin\]), and OPN (osteopontin) using the Kidney Injury Panel 1 (rat) Assay Kit manufactured by Meso Scale Diagnostics (Gaithersburg, MD). The multiplex assay plate was read on a Meso Scale Diagnostics SECTOR Imager 2400 electrochemiluminescence plate reader. Biomarkers were determined in 8 animals per group and normalized to urine creatinine levels measured by high‐performance liquid chromatography as described above.

Anti--Double‐Stranded DNA ELISA {#jah34776-sec-0021}
-------------------------------

Activated calf thymus DNA (Sigma, D4522) was bound to UV‐activated Immunlon 2B ELISA plates and washed 5 times. Diluted serum samples (1:30) were incubated for 1 hour at room temperature and subsequently washed, and horseradish peroxidase--conjugated anti--rat IgM or IgG was added to the wells for a further 1 hour before rinsing and developing with TMB substrate. Reactions were stopped with sulfuric acid, and the developed color measured at 450 nmol/L by plate reader.

Renal Immunofluorescence {#jah34776-sec-0022}
------------------------

Detection of glomerular immunoglobulin deposition was performed on frozen tissue sections. Tissue was incubated with AlexaFluor488‐tagged goat anti--rat IgM (Southern Biotech, Inc, Birmingham, AL) or biotin‐tagged goat anti--rat IgG (Bio‐Rad Laboratories, Inc, Hercules, CA) for 1 hour at a dilution of 1:500. FITC‐streptavidin (1:1000 for 1 hour) was used as the detection antibody. Twenty glomeruli from each rat were assessed by an investigator blinded to the rat genotypes. Images were captured on a Nikon Eclipse TE2000E wide‐field fluorescence microscope at a magnification ×400 and with an exposure time of 500 ms for all images.

HuProt Antigen Microarray Studies {#jah34776-sec-0023}
---------------------------------

These studies were performed in the Genomics and Microarray Core Facility, University of Texas Southwestern Medical School, Dallas, TX. HuProt v3.1 arrays (CDI Laboratories, Mayaguez, PR) spotted in duplicate with more than 20 000 full‐length recombinant human proteins representing \>80% of the human proteome were used according to the manufacturer\'s published protocol. Each individual array was incubated with pooled serum collected from 6 individual animals of each SHR line (SHR‐A3, SHR‐B2, SHR‐A3(*Stim1*‐B2) congenic) at 40 weeks of age. Arrays were developed with detection antibodies targeting rat IgM and rat IgG (goat polyclonal anti--rat IgM‐heavy chain conjugated with Alexa Fluor 647 and goat polyclonal anti--rat IgG \[H+L\] conjugated with Cyanine3, both from Invitrogen, Carlsbad, CA) and read on a fluorescent slide reader (GenePix 4400A Microarray Scanner, Molecular Devices, Sunnyvale, CA). Z score normalization was used to permit comparison of autoantibody signals across arrays. Intra‐array reproducibility was assessed by analyzing correlation of signals between duplicate spots.

Blood Pressure Measurements {#jah34776-sec-0024}
---------------------------

At 16 to 17 weeks of age, male SHR‐A3 and SHR‐A3(*Stim1*‐B2) rats were implanted with radiotelemetry devices (Data Sciences, St. Paul, MN) to record blood pressure (BP), as described.[21](#jah34776-bib-0021){ref-type="ref"} Animals were allowed to recover for at least 1 week before initiating BP recordings. BP was measured by continuous sampling for 30 seconds every 30 minutes for 24 hours at 18 weeks of age, before the emergence of histological renal injury,[8](#jah34776-bib-0008){ref-type="ref"} to determine whether the *Stim1* mutation affects baseline (pre--renal injury) BP.

Statistical Analyses {#jah34776-sec-0025}
--------------------

Comparison of data from SHR‐A3 and SHR‐B2 rats was done by Student t test using Prism 7 software (GraphPad Software, La Jolla, CA). ANOVA with Tukey post‐hoc test was used to compare data from multiple groups. A value of *P*\<0.05 was considered statistically significant, with n=5 to 7 independent replicates per group.

Results {#jah34776-sec-0026}
=======

*Stim1*‐Rescued SHR‐A3 Congenic Line Creation {#jah34776-sec-0027}
---------------------------------------------

Figure [1](#jah34776-fig-0001){ref-type="fig"} indicates the location of identical genomic blocks that are shared by descent in SHR‐A3 and SHR‐B2 and the position of the *Stim1* gene. These haplotype blocks were originally located by high‐density SNP analysis. Subsequently we have obtained whole‐genome sequence information for these rat lines that, in addition to identifying the *Stim1* mutation, allowed us to confirm the distribution of identity by descent in the genomes of the 2 rat lines. Table [S1](#jah34776-sup-0001){ref-type="supplementary-material"} provides a list of coding sequence variations from the rat reference genome sequence that are present in SHR‐A3 and SHR‐B2. This listing was computed by Annovar software[19](#jah34776-bib-0019){ref-type="ref"} from Illumina short‐read resequencing of the SHR‐A3 and SHR‐B2 genomes with \>45X read depth coverage.[9](#jah34776-bib-0009){ref-type="ref"} In this block from chr1:156 969 388‐198 720 287 (Rn6 assembly of the rat reference genome), the only coding base location in which SHR‐A3 and SHR‐B2 differ from each other is in *Stim1* at chr1:167 531 867 (Rn6) in which SHR‐A3 has a SNP creating a premature stop codon. All other variations from the rat reference sequence in this block are shared by both SHR‐A3 and SHR‐B2.

![Chromosome scale view of congenic transfer of an identical‐by‐descent (IBD) haploblock containing wild‐type *Stim1* from SHR‐B2 in the SHR‐A3 genetic background. **A**, Regions of genetic IBD sequences are shown for the SHR‐A3 and SHR‐B2 genomes (20 autosomes and X chromosome. This block was initially identified by genotyping ≈10 000 genome‐wide SNPs. It has been confirmed, and its boundaries precisely defined, by whole‐genome sequencing. All SHR lines are the progeny of a single progenitor male and therefore lack ancestral Y chromosome variation). Red blocks indicate regions of the genome at which the 2 rat lines are descended from different ancestors. Solid black lines represent the remaining 87% of the genome that is IBD. **B**, Enlarged view of the rat chromosome 1 (Rno chr1) indicating the target haplotype block transferred from SHR‐B2 into the SHR‐A3 background. **C**, Detailed view of the approximate beginning and end points of the haplotype blocks surrounding the transferred segment (indicated to the right of the blocks and determined by examination of whole‐genome sequence alignments of SHR‐A3 and SHR‐B2). The genomic position of single‐nucleotide polymorphisms in this region that were genotyped in speed congenic construction are indicated above the colored blocks. Inheritance of the *Stim1* wild‐type allele was determined by PCR amplification of the sequence including the polymorphic site. *Stim1* genotype was determined by restriction digestion of the PCR products with AluI, which digests the SHR‐A3 mutated sequence but not the wild‐type SHR‐B2 sequence. PCR indicates polymerase chain reaction; SHR, spontaneously hypertensive rat; SNP, single‐nucleotide polymorphism.](JAH3-9-e014142-g001){#jah34776-fig-0001}

Genotypes of SNPs present on rat Chr1 in SHR‐A3 and SHR‐B2 and used to initially identify the *Stim1*‐containing block are provided in Table [S2](#jah34776-sup-0002){ref-type="supplementary-material"} and demonstrate the distribution of identical‐by‐descent sequences on this chromosome. The *Stim1* polymorphism creates a premature stop codon and is located at chr1:167 531 867 (Rn6) in a 45‐Mb block that is otherwise identical by descent between SHR‐A3 and SHR‐B2. Our previously described strategy of marker‐assisted genotyping of SHR‐B2 animals backcrossed onto the SHR‐A3 genetic background[9](#jah34776-bib-0009){ref-type="ref"} was used to create a congenic line in which the *Stim1* haploblock from SHR‐B2 was transferred to SHR‐A3.

Effect of *Stim1* Gene Rescue on Renal Injury {#jah34776-sec-0028}
---------------------------------------------

We used histological assessments and urinary albumin and injury biomarker excretion to evaluate hypertensive renal injury in SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) rats. Figure [2](#jah34776-fig-0002){ref-type="fig"} indicates the presence of significant glomerular and tubulointerstitial injury in 40‐week‐old SHR‐A3 when compared with age‐matched SHR‐B2 rats. Histological measures of renal injury were reduced to SHR‐B2 levels in the *Stim1* rescue congenic line (Figure [3](#jah34776-fig-0003){ref-type="fig"}A). Urinary biomarker excretion provides an opportunity to evaluate ongoing injury to the renal epithelium, particularly proximal tubular cells. We assessed urinary levels of 3 established markers of renal injury (OPN, NGAL, KIM‐1) at 30 weeks of age and found a high level of divergence between biomarker excretion in SHR‐A3 and SHR‐B2 rats (Figure [3](#jah34776-fig-0003){ref-type="fig"}B). *Stim1* congenic rats had markedly reduced levels of these markers of renal injury. Albuminuria, however, remained high in SHR‐A3(*Stim1*‐B2) rats (Figure [3](#jah34776-fig-0003){ref-type="fig"}C), which suggests that this element of renal injury may arise from regions of the SHR‐A3 genome outside the *Stim1* locus. BP at 18 weeks, before the emergence of renal injury, was comparable between the SHR‐A3 and SHR‐A3(*Stim1*‐B2) rats ([Table](#jah34776-tbl-0001){ref-type="table"}), which implies that the *Stim1* mutation contributes susceptibility to glomerular and tubulointerstitial injury in SHR‐A3 independent of BP effects.

![Effect of the *Stim1* mutation on renal injury. Representative PAS‐stained kidney sections (upper panels, ×20; lower panels, ×40 magnification) from 40‐week‐old SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) rats. PAS indicates periodic acid Schiff stain.](JAH3-9-e014142-g002){#jah34776-fig-0002}

![Renal injury and T‐cell infiltration in SHR‐A3, SHR‐B2 and SHR‐A3(*Stim1*‐B2). **A**, Glomerular (Glom) and tubulointerstitial (TI) injury scores, n=8 (SHR‐A3), 18 (SHR‐B2), 10 (SHR‐A3\[*Stim1*‐B2\]). **B**, Urinary renal injury biomarker levels for neutrophil gelatinase‐associated lipocalin (NGAL), osteopontin (OPN), and kidney injury molecule‐1 (KIM‐1) normalized to creatinine excretion in urine collected from 30‐week‐old SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) rats, n=8. **C**, Urinary albumin excretion normalized to urinary creatinine in 40‐week‐old SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) rats; n=23 (SHR‐A3), 19 (SHR‐B2), 14 (SHR‐A3\[*Stim1*‐B2\]). \**P*\<0.05 vs SHR‐A3 and ^\#^ *P*\<0.05 vs SHR‐B2. Flow cytometric analysis of (**D**) T and B cells, (**E**) CD4^+^ and CD8^+^ T‐cell subsets, and (**F**) T~reg~s in kidneys from 40‐week‐old SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) rats; n=5 rats. \**P*\<0.05 vs SHR‐A3 and ^\#^ *P*\<0.05 vs SHR‐B2. T~reg~ indicates regulatory T cells; uACR, urinary albumin/creatinine ratio.](JAH3-9-e014142-g003){#jah34776-fig-0003}

###### 

Blood Pressure in 18‐Week‐Old Rats

  Strain                     SBP (mm Hg)     MBP (mm Hg)     DBP (mm Hg)     HR (bpm)
  -------------------------- --------------- --------------- --------------- ---------------
  SHR‐A3 (n=10)              194.6±6.6       170.1±5.8       145.3±6.4       318.7±7.9
  SHR‐A3(*Stim1*‐B2) (n=8)   196.5±1.5^NS^   166.8±1.8^NS^   136.9±2.1^NS^   310.5±4.9^NS^

BP and HR were compared by Student t test where *P*\<0.05 was considered statistically significant. HR indicates heart rate; NS, not statistically significant; SBP, MBP, DBP, systolic, mean, and diastolic arterial blood pressure.

SHR‐A3 kidneys were characterized by extensive T‐ and B‐cell infiltration (Figure [3](#jah34776-fig-0003){ref-type="fig"}D) compared with SHR‐B2. Absolute CD4^+^ and CD8^+^ T‐cell counts were significantly higher in SHR‐A3 kidneys than in SHR‐B2 and were markedly reduced by *Stim1* gene rescue in the congenic line (Figure [3](#jah34776-fig-0003){ref-type="fig"}E). On the other hand, the relative percentages of renal CD3^+^CD4^+^CD25^+^Foxp3^+^ T~reg~s were higher in SHR‐B2 and SHR‐A3(*Stim1*‐B2) rats (Figure [3](#jah34776-fig-0003){ref-type="fig"}F).

Effect of the *Stim1* Mutation on Lymphocyte Calcium Signaling and T‐Cell Development {#jah34776-sec-0029}
-------------------------------------------------------------------------------------

To assess the contribution of *Stim1* mutation to susceptibility to renal injury in SHR‐A3, we created a congenic *Stim1* rescue line, SHR‐A3(*Stim1*‐B2). in which the defective *Stim1* present in SHR‐A3 was replaced with the wild‐type *Stim1* allele from SHR‐B2. The SHR‐A3 *Stim1* nonsense mutation leads to the truncation of 46 amino acids from the C‐terminal domain.[7](#jah34776-bib-0007){ref-type="ref"} The mutation does not activate non--sense‐mediated RNA decay because it is located in the terminal exon of the gene. Western blotting was used to investigate STIM1 protein expression using an antibody targeting the N‐terminus of STIM1. SHR‐A3 rats had the expected reduction in apparent molecular weight of STIM1 compared with SHR‐B2 and SHR‐A3(*Stim1*‐B2) rats, which express the "wild type" STIM1 (Figure [4](#jah34776-fig-0004){ref-type="fig"}A). Protein abundance of STIM1 was comparable among SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) lines (Figure [4](#jah34776-fig-0004){ref-type="fig"}B). STIM1 antibodies targeting the deleted C‐terminus of STIM1 detected protein in SHR‐B2 but not SHR‐A3.[7](#jah34776-bib-0007){ref-type="ref"}

![Effect of the *Stim1* mutation on SOCE and NFAT activation in CD4^+^ T cells. **A**, Representative Western blot using N‐terminal--directed antibodies demonstrates the presence of STIM1 protein in SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) T lymphocytes. **B**, Summary graph showing the results from densitometric analyses of STIM1 bands normalized to the intensities of total protein bands; n=5 per group. **C**, Average time course for \[Ca^2+^\]~i~ influx in response to store depletion by thapsigargin (TG, 2 μmol/L) followed by Ca^2+^ readdition to induce SOCE. **D**, Average time course for \[Ca^2+^\]~i~ influx in response to anti‐CD3 followed by CD3 cross‐linking with streptavidin (SA) and Ca^2+^ readdition to induce SOCE. **E**, Summary graph of sustained phases of TG‐induced Ca^2+^ influx. **F**, Summary graph showing peak \[Ca^2+^\]~i~ levels in response to CD3 cross‐linking in SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) CD4^+^ T cells. **G**, Confocal microscopy of NFATc1 nuclear translocation in SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) lymphocytes stimulated for 60 minutes with PMA (10 nmol/L) and ionomycin (2 μmol/L). Green indicates NFATc1 staining, and red indicates nuclear stain using Draq5. **H**, Summary graph of 3 independent experiments showing the percentage of lymphocytes with NFAT nuclear translocation. Scale bar=1 μm. \**P*\<0.05 vs SHR‐A3 with n=5 per group. Summary graphs of circulating (**I**) CD4^+^ and (**J**) CD8^+^ T‐cell frequencies as a percentage of total CD3^+^ T cells in SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) rats. **K**,CD4^+^ CD25^+^Foxp3^+^ T~reg~ cell frequencies as a percentage of total CD3^+^ T cells in peripheral blood (PB), aortic lymph nodes (LN) and spleens (SPL) from SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) rats. \**P*\<0.05 vs SHR‐A3 with n=5 to 7 per group. Iono indicates ionomycin; NFAT, nuclear factor of activated T cells; PMA, phorbol myristate acetate; SOCE, store‐operated calcium entry; US, unstimulated.](JAH3-9-e014142-g004){#jah34776-fig-0004}

The *Stim1* mutation in SHR‐A3 deletes the downstream lysine‐rich polybasic carboxyl terminus of STIM1, but leaves intact the STIM1 region responsible for gating of ORAI1 capacitative calcium entry channel. The polybasic region has been shown to facilitate and stabilize coupling of STIM1‐ORAI1 and thus regulate the strength of the SOCE signal.[22](#jah34776-bib-0022){ref-type="ref"} Accordingly, we expected that SHR‐A3 T cells would demonstrate diminished SOCE in response to ER store depletion. Thapsigargin‐ and TCR‐induced SOCE were markedly reduced in CD4^+^ T cells from SHR‐A3 when compared with SOCE in SHR‐B2 and SHR‐A3(*Stim1*‐B2) T cells (Figure [4](#jah34776-fig-0004){ref-type="fig"}C through [4](#jah34776-fig-0004){ref-type="fig"}F). SOCE in SHR‐B2 and SHR‐A3(*Stim1*‐B2) CD4^+^ T cells was suppressed when opening of the ORAI1 channel was inhibited with Pyr6 (not shown), confirming that STIM1‐ORAI1 is the major pathway for SOCE in rat T cells. To test if deficient SOCE impairs calcineurin‐mediated dephosphorylation of NFAT, we examined NFAT nuclear translocation in response to activation of SOCE. Lymphocytes from SHR‐A3 rats have a significant impairment in NFAT activation compared with SHR‐B2 lymphocytes in response to ER Ca^2+^ depletion with PMA 10 nmol/L and ionomycin 2 μmol/L (Figure [4](#jah34776-fig-0004){ref-type="fig"}G and [4](#jah34776-fig-0004){ref-type="fig"}H). Defective NFAT activation was rectified by *Stim1* gene rescue in the congenic line.

SOCE is dispensable for CD4^+^ and CD8^+^ T cell development.[23](#jah34776-bib-0023){ref-type="ref"} As expected, we found comparable levels of these T cell frequencies in our 3 rat strains (Figure [4](#jah34776-fig-0004){ref-type="fig"}I and [4](#jah34776-fig-0004){ref-type="fig"}J). In contrast, CD4^+^ T cell SOCE is required for T regulatory cell (T~reg~) differentiation.[17](#jah34776-bib-0017){ref-type="ref"}, [23](#jah34776-bib-0023){ref-type="ref"} CD4^+^CD25^+^Foxp3^+^ T~reg~ numbers were significantly reduced in peripheral blood, spleens, and lymph nodes from SHR‐A3 (Figure [4](#jah34776-fig-0004){ref-type="fig"}K).

Effect of the *Stim1* Mutation on CD4^+^ T Cell Effector and Regulatory Function {#jah34776-sec-0030}
--------------------------------------------------------------------------------

The production of cytokines, particularly IL‐2 and IFNγ, is an important SOCE‐dependent immune effector function of CD4^+^ T cells.[23](#jah34776-bib-0023){ref-type="ref"} SHR‐A3 CD4^+^ T cells produced markedly lower amounts of IL‐2 and IFNγ in response to TCR‐specific antibody stimulation using anti‐CD3/anti‐CD28 compared with SHR‐B2 rats (Figure [5](#jah34776-fig-0005){ref-type="fig"}A and [5](#jah34776-fig-0005){ref-type="fig"}B). This defect in cytokine production was rectified in T cells from the *Stim1* rescued congenic line. Upregulation of IL‐2α (CD25) in response to TCR stimulation, a process largely under the transcriptional control of NFκB[24](#jah34776-bib-0024){ref-type="ref"} and independent of SOCE via STIM1‐ORAI1,[23](#jah34776-bib-0023){ref-type="ref"} was used as a marker of T‐cell activation.[25](#jah34776-bib-0025){ref-type="ref"} SHR‐A3 T cells were activated by CD3/CD28 costimulation for 24 hours. CD25 expression was comparable between SHR‐A3 and SHR‐B2 CD4^+^ T cells and was unaffected by inhibition of STIM1‐ORAI1 signaling with Pyr6 (Figure [5](#jah34776-fig-0005){ref-type="fig"}C).

![Effect of the *Stim1* mutation on CD4^+^ T‐cell function. Quantification of (**A**) IFNγ and (**B**) IL‐2 production by CD4^+^ T cells from SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) rats in response to anti‐CD3/anti‐CD28 costimulation for 24 hours under nonpolarizing conditions. A subset of cells was pretreated with the ORAI1 channel blocker Pyr6 (5 μmol/L) for 15 minutes before the addition of CD28. **C**, Upregulation of the activation marker CD25 on CD4^+^ T cells after 18 hours of TCR stimulation with anti‐CD3/anti‐CD28. Pretreatment of T cells with Pyr6 did not prevent CD25 expression. Data are representative of 3 independent experiments. **D**, Histograms showing the intensity peaks of CFSE as an indicator of CD4^+^ T‐cell proliferation in response to TCR stimulation using anti‐CD3/anti‐CD28 for 72 hours in (**upper panels**) SHR‐A3, and (**lower panels**) SHR‐B2 and SHR‐A3(*Stim1*‐B2) cells. Each peak represents 1 cell division in stimulated cells. **E**, Summary graph of total percentage of CD4^+^ T cells undergoing at least 1 cell division. **F**, Summary graph of Annexin V^+^ CD4^+^ T cells from SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) rats in response to 24‐hour restimulation with anti‐CD3/anti‐CD28 after the initial 72‐hour TCR stimulation with anti‐CD3 and anti‐CD28. \**P*\<0.05 vs SHR‐A3 and ^\#^ *P*\<0.05 vs SHR‐B2 with n=6 per group. CFSE indicates carboxyfluorescein succinimidyl ester; IFNγ, interferon‐γ; IL‐2, interleukin‐2; TCR, T‐cell receptor.](JAH3-9-e014142-g005){#jah34776-fig-0005}

Proliferation induced in CD4^+^ T cells by CD3/CD28 costimulation for 72 hours was assessed by the CFSE dilution method[23](#jah34776-bib-0023){ref-type="ref"} (Figure [5](#jah34776-fig-0005){ref-type="fig"}D). At the end of the stimulation protocol, 70% to 80% of SHR‐B2 and SHR‐A3(*Stim1*‐B2) T cells had undergone at least 1 cell division. CD4^+^ T cells from SHR‐A3 exhibited a weak proliferative response, and only about 20% of cells underwent proliferation. SHR‐A3 CD4^+^ T cells failed to proliferate further in response to TCR activation, whereas SHR‐B2 and SHR‐A3(*Stim1*‐B2) cells continued to 2 or 3 cell divisions (Figure [5](#jah34776-fig-0005){ref-type="fig"}E). In addition to T‐cell effector functions, STIM1‐driven SOCE mediates activation‐induced T‐cell apoptosis.[26](#jah34776-bib-0026){ref-type="ref"}, [27](#jah34776-bib-0027){ref-type="ref"} To mimic sustained inflammatory conditions in vitro, CD4^+^ T cells were restimulated with anti‐CD3/anti‐CD28 for 24 hours after an initial 72‐hour TCR‐induced activation. Restimulation resulted in significantly lower counts of annexin V^+^ apoptotic cells among SHR‐A3 than SHR‐B2 and SHR‐A3(*Stim1*‐B2) CD4^+^ T cells (Figure [5](#jah34776-fig-0005){ref-type="fig"}F). Thus, the impaired proliferative responses to TCR stimulation in SHR‐A3 may be countered by suppression of apoptotic responses during sustained TCR stimulation.

Antibody Formation and STIM1 Function {#jah34776-sec-0031}
-------------------------------------

STIM1 function is essential for antibody affinity maturation, and its deficiency is associated with the emergence of autoantibodies.[17](#jah34776-bib-0017){ref-type="ref"} Animals were studied at 40 weeks of age to determine whether renal injury could be linked to deposition of immunoglobulins in the glomerulus. Glomerular IgM and IgG were detectable in all 3 lines (Figure [6](#jah34776-fig-0006){ref-type="fig"}A); however, staining intensity for both immunoglobulins was higher in SHR‐A3 kidneys than in SHR‐B2. Glomerular staining for IgM and IgG in the SHR‐A3(*Stim1*‐B2) line was intermediate between the level observed in SHR‐A3 and that in SHR‐B2.

![Renal IgM and IgG in SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2). **A**, Representative images of immunofluorescent detection of IgM (**upper panels**) and IgG (**lower panels**) in kidneys from 40‐week‐old SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) rats; n=5 to 6 rats. Original magnification ×400 and with an exposure time of 500 ms for all images. **B**, Serum ELISAs of anti--ds‐DNA for IgM (**upper panels**) and IgG (**lower panels**) in 18‐ and 40‐week‐old SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) rats; n=9 (SHR‐A3), 6 (SHR‐B2), 9 (SHR‐A3\[*Stim1*‐B2\]). \**P*\<0.05 vs SHR‐A3 and ^\#^ *P*\<0.05 vs SHR‐B2.](JAH3-9-e014142-g006){#jah34776-fig-0006}

Elevated levels of antinuclear antibodies (anti--double‐stranded \[ds\]‐DNA, anti--Ro60/SSA, anti--La/SSB) have been described in the serum from mice and humans with defective SOCE.[17](#jah34776-bib-0017){ref-type="ref"} We have examined the presence of anti--ds‐DNA antibodies in serum from the 3 rat lines. Serial dilutions of serum from 40‐week‐old SHR‐A3 and SHR‐B2 were strongly divergent with much greater binding observed in SHR‐A3 serum. Serum from SHR‐A3(*Stim1*‐B2) had significantly lower levels of anti--ds‐DNA IgG antibodies at 18 weeks of age, before the onset of renal injury (Figure [6](#jah34776-fig-0006){ref-type="fig"}B). At this age, IgM levels were comparable between SHR‐A3 and SHR‐A3(*Stim1*‐B2). However, at 40 weeks, when renal injury was established, IgG levels were comparable between SHR‐A3 and SHR‐A3(*Stim1*‐B2), whereas IgM levels in SHR‐A3(*Stim1*‐B2) were intermediate between those of SHR‐A3 and SHR‐B2 (Figure [6](#jah34776-fig-0006){ref-type="fig"}B).

We used HuProt 3.1 arrays to identify protein targets of autoantibody reactivity in the serum of SHR‐A3, SHR‐B2, and SHR‐A3(*Stim1*‐B2) congenic animals. After incubation with rat serum, arrays were interrogated with fluorescently conjugated anti--rat IgM and IgG detection antibodies. We sorted signals by highest intensity in SHR‐A3 using a Z score cutoff of \>10. This identified 41 IgM and 34 IgG targets. Among these targets with high SHR‐A3 signals, 22 were common to both IgM and IgG. In 2 cases, unique array targets that represent different isoforms of the same protein generated signals with a Z score \>10 for each of the isoforms (SSBP3, BCAR1). In addition to replication of the SSBP3 signal for 2 unique SSBP3 isoforms, SSBP2 also produced an SHR‐A3 signal with Z score \>10 in both IgM and IgG. Full details of detected reactivities are provided as Table [S3](#jah34776-sup-0003){ref-type="supplementary-material"}.

Discussion {#jah34776-sec-0032}
==========

Susceptibility to hypertensive renal injury is not uniformly distributed in the hypertensive population and is strongly influenced by genetic factors. Large‐scale human population genetics studies intended to uncover the genetic variants that permit hypertension to initiate and perpetuate renal injury have resulted in limited progress. SHR lines share interesting features in common with human hypertensives: elevated BP has a genetic component that arises from natural genetic variants. These variants were rapidly fixed in SHR by selection on the trait of BP.[28](#jah34776-bib-0028){ref-type="ref"} The subsequent separation of distinct SHR lines has resulted in lines that also mirror the human hypertensive population: natural genetic variation contributes to susceptibility to hypertensive renal injury but is not uniformly distributed among the hypertensive population.[29](#jah34776-bib-0029){ref-type="ref"} The objective of genetic studies of hypertensive renal injury in SHR is to identify genetic variation that can interact with high BP to result in renal disease. Knowledge of the genes involved in SHR disease and their function may illuminate a pathogenic pathway that leads to progressive loss of renal function in hypertension that is generalizable beyond hypertensive rats. Our prior work in SHR implicates germ‐line genetic variation in the immunoglobulin heavy chain gene, a gene that encodes the preimmune repertoire, in determining susceptibility to renal injury.[9](#jah34776-bib-0009){ref-type="ref"}, [30](#jah34776-bib-0030){ref-type="ref"} Genetic defects of *Stim1* are also associated with antibody‐mediated autoimmunity.[16](#jah34776-bib-0016){ref-type="ref"}, [17](#jah34776-bib-0017){ref-type="ref"}, [18](#jah34776-bib-0018){ref-type="ref"} These observations indicate a potential role for antibodies in hypertensive renal disease in SHR.

We have constructed the *Stim1* rescue congenic line using high‐density SNP genotyping and whole genome sequencing data. We identified a large block on chromosome 1 in which SHR‐A3 and SHR‐B2 have inherited genomic sequence from a single shared ancestor. Within this block we identified a single coding sequence change that affects *Stim1* in SHR‐A3 only. This is the only coding sequence mutation by which SHR‐A3 and SHR‐B2 differ in this block (Table [S1](#jah34776-sup-0001){ref-type="supplementary-material"}) and appears to be a relatively recent mutation. Examination of SNP data from 40 inbred rat lines[31](#jah34776-bib-0031){ref-type="ref"} indicates it is found only in SHR‐A3. Hitchhiker effects normally limit the ability to assign traits to a single variant in a congenic block. However, transfer of wild‐type *Stim1* from within a large block in which SHR‐A3 and SHR‐B2 are otherwise genetically identical eliminates the transfer of linked genetic variation.

The immune phenotype created by *Stim1* mutation in SHR‐A3 provides further support to our earlier studies indicating that the genetic pathway to end‐organ injury in SHR‐A3 arises from altered immune function.[5](#jah34776-bib-0005){ref-type="ref"}, [9](#jah34776-bib-0009){ref-type="ref"}, [30](#jah34776-bib-0030){ref-type="ref"} We show here that *Stim1* mutation disrupts lymphocyte calcium signaling, prevents NFAT nuclear localization, and blocks cytokine and proliferative responses to T‐lymphocyte activation. T‐lymphocyte functions include the provision of help to antibody‐producing B lymphocytes. *Stim* deficiency limits the ability of T cells to provide effective help to B‐cell antibody affinity maturation,[17](#jah34776-bib-0017){ref-type="ref"}, [18](#jah34776-bib-0018){ref-type="ref"}, [32](#jah34776-bib-0032){ref-type="ref"} and spontaneous autoantibody‐mediated disease occurs in humans lacking *Stim1* [16](#jah34776-bib-0016){ref-type="ref"}, [33](#jah34776-bib-0033){ref-type="ref"} and in targeted mice in which SOCE is eliminated by T‐cell targeting of both *Stim1* and *Stim2*.[17](#jah34776-bib-0017){ref-type="ref"}, [32](#jah34776-bib-0032){ref-type="ref"} These mice exhibit increased renal immunoglobulin deposits.[17](#jah34776-bib-0017){ref-type="ref"} Elevated levels of antinuclear antibodies (anti--ds‐DNA, anti--Ro60/SSA, anti--La/SSB) have been described in the serum from mice and humans with defective SOCE.[17](#jah34776-bib-0017){ref-type="ref"} The presence of higher levels of glomerular immunoglobulin depositions in SHR‐A3 than seen in SHR‐B2 or SHR‐A3(*Stim1*‐B2) and of increased levels of anti--ds‐DNA antibodies in the same pattern further suggests the emergence of antibody‐mediated autoimmune disease in SHR‐A3 and its amelioration by congenic substitution with functional STIM1. We have reported that differential susceptibility to renal injury in SHR‐A3 is also influenced by extensive variation in the immunoglobulin heavy chain (IgH) gene,[9](#jah34776-bib-0009){ref-type="ref"}, [34](#jah34776-bib-0034){ref-type="ref"} which encodes the preimmune antibody repertoire and may confer predisposition to autoreactive antibody formation. The contribution of impaired T‐cell effector function reported here indicates a defect in T‐cell help to B cells, an essential component of antibody affinity maturation that likely contributes, along with preexisting germline variation in IgH, to the pathogenesis of renal disease in this model. This interaction between 2 loci, both of which determine the expressed IgG and IgM repertoires but at different stages of autoantibody production, might explain why restoration of STIM1 function alone was not sufficient to reduce anti--ds‐DNA to SHR‐B2 levels. Interestingly autoantibody reactivity to single‐stranded DNA‐binding proteins (SSBP2, SSBP3) was detected in SHR‐A3 using the HuProt array, with lower levels of such signals in SHR‐B2 and SHR‐A3(*Stim1*‐B2). Autoantibodies against nucleic acid binding proteins are a common feature of systemic lupus erythematosus and suggest possible overlap in pathogenic mechanism in renal injury in lupus nephritis and in hypertensive renal injury in SHR‐A3.[35](#jah34776-bib-0035){ref-type="ref"} Our efforts to limit B‐cell function in SHR‐A3 using an anti‐CD20 antibody reactive to murine CD20 (Genentech, South San Francisco, CA; anti‐CD20 clone 5D2) failed to elicit sustained reductions in B‐cell counts. After an initial sharp fall in blood B‐cell count, SHR‐A3 B‐cell counts returned to normal, and no sustained B‐cell suppression during the development of renal injury was achieved (data not shown). Other approaches to blocking autoantibody production in SHR‐A3 are currently being investigated but have been limited by the occurrence of sepsis.

STIM1 deficiency disrupts T~reg~‐cell development, resulting in reduced T~reg~ numbers.[26](#jah34776-bib-0026){ref-type="ref"}, [32](#jah34776-bib-0032){ref-type="ref"}, [36](#jah34776-bib-0036){ref-type="ref"} A similar finding in SHR‐A3 (Figure [3](#jah34776-fig-0003){ref-type="fig"}C) indicates reduced tolerance arising from *Stim1* mutation. Reduced T~reg~ counts appear to be a consequence of the dependence of expression of the T regulatory master phenotype transcription factor Foxp3 on NFAT function.[37](#jah34776-bib-0037){ref-type="ref"} Together our observations suggest involvement in SHR‐A3 end‐organ injury pathogenesis of a *Stim1*‐driven mechanism involving antibody‐mediated immunity and diminished tolerance. This is also supported by our previously reported studies showing that the immunosuppressant drug mycophenolate mofetil reduces end‐organ injury in SHR‐A3.[38](#jah34776-bib-0038){ref-type="ref"} Mycophenolate mofetil acts to reduce cell proliferation by inhibiting a nucleic acid synthesis pathway that is exclusive to proliferating T and B lymphocytes.[39](#jah34776-bib-0039){ref-type="ref"}

Effects of *Stim1* mutation on end‐organ injury are dependent on the presence of hypertension because pharmacological lowering of BP prevents end‐organ injury in SHR‐A3.[40](#jah34776-bib-0040){ref-type="ref"} We observed that *Stim1* mutation has no effect on BP levels in 18‐week‐old animals before the emergence of renal injury.

Our model organism studies can be considered in light of heritability of risk of hypertensive end‐organ injury in humans. *Stim1* mutation that causes a complete loss of SOCE produces a severe phenotype and occurs only rarely in humans. However, *Stim* deficiency disrupts T‐cell interactions with B cells.[17](#jah34776-bib-0017){ref-type="ref"}, [18](#jah34776-bib-0018){ref-type="ref"} Numerous examples of genetic variation in other genes have been identified in human populations that impair T cell--B cell interaction and have been shown to be involved in autoimmune disease.[41](#jah34776-bib-0041){ref-type="ref"} The pathogenic alleles are not rare in the population and contribute importantly to autoimmune disease risk. The effects of *Stim1* mutation may reflect several functionally similar known immunopathogenic human gene variations that may contribute to end‐organ injury in the presence of hypertension, including common variants that affect lymphocyte receptor‐induced calcium signaling.[42](#jah34776-bib-0042){ref-type="ref"}, [43](#jah34776-bib-0043){ref-type="ref"}

In conclusion, we have identified genetic variation in SHR‐A3 affecting *Stim1*. We have shown that this variation contributes to the risk of hypertensive renal disease. As with all germ‐line mutations, phenotypic effects may occur in any cell or tissue with STIM1 function. Congenic replacement of truncated *Stim1* with the wild‐type allele restores a major defect in immune function in SHR‐A3. Concurrently, the ability of hypertension to elicit damage to the kidney is reduced. This may indicate that the major immune phenotype produced by the *Stim1* mutation participates in renal injury in SHR‐A3, and this may include injury contributed by autoantibody formation that interferes with T‐cell help to B cells. However, other functional defects arising from *Stim1* mutation may also participate in injury.
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